Extra Credit Educational Sessions

Objectives:

By participating in this learning program, health care providers can expect to:

• Understand the latest clinical developments in adjuvant immunotherapy for early-stage RCC.
• Describe the essential role of the Urologist encompassing initial consultations, referrals, inter-professional communication, and multi-disciplinary teamwork in diagnosis and treatment of RCC.
• Explore the patient perspective to better understand their treatment goals, expectations of the healthcare team, and the crucial information needed to facilitate informed decision-making throughout their care journey.

Objectives:

By participating in this learning program, health care providers can expect to:

• Understand the latest testing and treatment considerations for advanced prostate cancer (PCa) patients with genetic mutations, including those with HRR and MMR mutations.
• Navigate complex advanced PCa cases across diverse healthcare settings.
• Leverage multi-disciplinary insights on effective adverse event management.
• Employ strategies to optimize multidisciplinary patient care plans.

Objectives:

By participating in this learning program, health care providers can expect to:

• Interpret current evidence and real-world practice insights to inform first-line treatment strategies for patients with locally advanced or metastatic urothelial carcinoma (mUC).
• Evaluate key clinical factors, including patient characteristics and toxicity considerations, to support individualized treatment decisions.
• Apply practical approaches to sequencing, toxicity management, and personalized care using real-world patient scenarios.

Objectives:

By participating in this learning program, health care providers can expect to:

• Review recent radioligand therapy (RLT) clinical and real-world (RW) results in mCRPC.
• Summarize the differences between clinical trials and RW data, focusing on a patient-centric approach to treatment.
• Share recent experiences of implementing a RLT centre.

Objectives:

By participating in this learning program, health care providers can expect to:

• Recognize the ongoing MIBC clinical trials and their potential impact on the current treatment paradigm.
• Identify patient management strategies for novel combinations being studied in MIBC.
• Reflect upon current institutional multi-disciplinary approaches to patient care.

Objectives:

By participating in this learning program, health care providers can expect to:

• Understand the multidisciplinary guidance within the Canadian Urological Association mCSPC guidelines
• Develop the appropriate referral pathways to optimally manage patients with mCSPC.
• Make clinical decisions through peer-to-peer and regional level consultations.

Objectives:

By participating in this learning program, health care providers can expect to:

• Define healthcare advocacy and its significance within the Canadian healthcare system.
• Leverage CUA resources including census data and statistics on wait times for urological services to push for progress on advocacy priorities.
• Develop and implement strategies to engage in effective advocacy at individual, bureaucratic, and political levels.

Objectives:

By participating in this learning program, health care providers can expect to:

• Evaluate the balance between early treatment intensification, patient outcomes, and quality of life.
• Apply emerging evidence to guide treatment intensification decisions in high-risk BCR and mCSPC.
• Determine the optimal timing and role of PSMA-PET in treatment decision-making.
• Identify best practices for combining RT, ADT, and/or ARPi to optimize patient outcomes.